PIK3CA and infantile convulsions and choreoathetosis: Our data substantiated the participation of CDK4/6 inhibition in iCCA and validated our hypothesis, providing the theoretical basis for the development of combination therapy, for instance, with the PI3K pathway inhibitor PF-04691502.